ENTRY       D05704                      Drug
NAME        Rasburicase (USAN/INN);
            Rasburicase (genetical recombination) (JAN);
            Elitek (TN)
PRODUCT     ELITEK (Sanofi-Aventis U.S. LLC)
SEQUENCE    C2H3O-SAVKAARYGK DNVRVYKVHK DEKTGVQTVY EMTVCVLLEG EIETSYTKAD
            NSVIVATDSI KNTIYITAKQ NPVTPPELFG SILGTHFIEK YNHIHAAHVN IVCHRWTRMD
            IDGKPHPHSF IRDSEEKRNV QVDVVEGKGI DIKSSLSGLT VLKSTNSQFW GFLRDEYTTL
            KETWDRILST DVDATWQWKN FSGLQEVRSH VPKFDATWAT AREVTLKTFA EDNSASVQAT
            MYKMAEQILA RQQLIETVEY SLPNKHYFEI DLSWHKGLQN TGKNAEVFAP QSDPNGLIKC
            TVGRSSLKSK L
  TYPE      Peptide
SOURCE      Aspergillus flavus [TAX:5059]
REMARK      Therapeutic category: 3959
            ATC code: V03AF07
            Product: D05704<JP/US>
EFFICACY    Uricolytic
COMMENT     urate oxidase [KO:K00365] [EC:1.7.3.3]
            Rasburicase is contraindicated in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency [DS:H00668] because this can precipitate hemolytic anemia.
            Treatment of malignancy-associated or chemotherapy-induced hyperuricemia
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             V VARIOUS
              V03 ALL OTHER THERAPEUTIC PRODUCTS
               V03A ALL OTHER THERAPEUTIC PRODUCTS
                V03AF Detoxifying agents for antineoplastic treatment
                 V03AF07 Rasburicase
                  D05704  Rasburicase (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Antineoplastic Adjuncts/Mitigators
               Rasburicase
                D05704  Rasburicase (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             3  Agents affecting metabolism
              39  Other agents affecting metabolism
               395  Enzyme preparations
                3959  Others
                 D05704  Rasburicase (USAN/INN); Rasburicase (genetical recombination) (JAN)
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D05704
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D05704
            Pharmacogenomic biomarkers [br08341.html]
             Polymorphisms and mutations affecting drug response
              D05704
DBLINKS     CAS: 134774-45-1
            PubChem: 47207365
///
